(Credit: Daniel Beckemeier/Shutterstock.com)

Eli Lilly and Co.’s announcement Wednesday that it plans to slash the list prices of its popular Humalog and Humulin insulin by 70% isn’t likely to free the company from an avalanche of litigation alleging it used its dominant market position to keep insulin prices high.

Among pending cases is one filed in 2017 against Lilly, Sanofi and Novo Nordisk alleging insulin-makers conspired with pharmacy benefit managers to increase the list price of their insulin products and then set a lower price for certain bulk drug distributors.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.